Chartwell Investment Partners LLC raised its position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) by 31.4% during the fourth quarter, Holdings Channel reports. The fund owned 120,546 shares of the company’s stock after acquiring an additional 28,831 shares during the quarter. Chartwell Investment Partners LLC’s holdings in Myriad Genetics were worth $4,140,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Meeder Asset Management Inc. grew its holdings in shares of Myriad Genetics by 1,067.4% in the third quarter. Meeder Asset Management Inc. now owns 3,292 shares of the company’s stock worth $119,000 after purchasing an additional 3,010 shares during the last quarter. LS Investment Advisors LLC grew its holdings in shares of Myriad Genetics by 88.5% in the fourth quarter. LS Investment Advisors LLC now owns 4,791 shares of the company’s stock worth $165,000 after purchasing an additional 2,250 shares during the last quarter. Commonwealth Equity Services Inc bought a new position in shares of Myriad Genetics in the third quarter worth about $202,000. Teacher Retirement System of Texas bought a new position in shares of Myriad Genetics in the third quarter worth about $204,000. Finally, Shelton Capital Management bought a new position in shares of Myriad Genetics in the third quarter worth about $238,000.
MYGN has been the topic of a number of research analyst reports. ValuEngine cut shares of Myriad Genetics from a “buy” rating to a “hold” rating in a report on Thursday, November 2nd. Morgan Stanley upped their price target on shares of Myriad Genetics from $24.00 to $26.00 and gave the stock an “underweight” rating in a report on Wednesday, November 8th. Deutsche Bank upped their price target on shares of Myriad Genetics from $28.00 to $30.00 and gave the stock a “hold” rating in a report on Wednesday, November 8th. Zacks Investment Research cut shares of Myriad Genetics from a “strong-buy” rating to a “hold” rating in a report on Friday, December 15th. Finally, Stephens set a $45.00 price target on shares of Myriad Genetics and gave the stock a “buy” rating in a report on Wednesday, January 3rd. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $31.42.
Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) opened at $32.81 on Monday. Myriad Genetics, Inc. has a one year low of $17.09 and a one year high of $41.57. The firm has a market cap of $2,290.00, a PE ratio of 17.83, a P/E/G ratio of 2.32 and a beta of 0.32. The company has a quick ratio of 1.81, a current ratio of 2.05 and a debt-to-equity ratio of 0.05.
Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings data on Tuesday, February 6th. The company reported $0.31 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.24 by $0.07. Myriad Genetics had a net margin of 16.55% and a return on equity of 14.43%. The company had revenue of $194.00 million during the quarter, compared to analyst estimates of $188.72 million. During the same period in the prior year, the firm earned $0.26 earnings per share. The firm’s revenue for the quarter was down 1.3% compared to the same quarter last year. analysts anticipate that Myriad Genetics, Inc. will post 1.15 EPS for the current year.
About Myriad Genetics
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.
Want to see what other hedge funds are holding MYGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myriad Genetics, Inc. (NASDAQ:MYGN).
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.